Biomarkers and surrogate endpoints: how and when might they impact drug development?

Biomarkers and surrogate endpoints: how and when might they impact drug development?

Item
http://www.wikidata.org/entity/Q34938801
Quantitative biomarker analysis of synovial gene expression by real-time PCRHow clinical trials of myasthenia gravis can inform pre-clinical drug developmentMicrovesicles/exosomes as potential novel biomarkers of metabolic diseasesThe Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogatUse of functional imaging across clinical phases in CNS drug development.Industry perspectives on biomarker qualification.Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.Metrological sharp shooting for plasma proteins and peptides: The need for reference materials for accurate measurements in clinical proteomics andin vitro diagnostics to generate reliable results
P2860

Biomarkers and surrogate endpoints: how and when might they impact drug development?

Item
http://www.wikidata.org/entity/Q34938801
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@ast
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@en
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@nl
type
label
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@ast
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@en
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@nl
prefLabel
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@ast
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@en
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Biomarkers and surrogate endpoints: how and when might they impact drug development?
@en
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932